From the spark of the therapeutic idea until the placement of a drug on a pharmacy shelf, any novel treatment has a long way ahead. Most of them take decades to be available for patients, and the average cost of developing a new therapy rises to up to millions of euros. This drain of time and money is due to … Read More
An intestinal simulation for a real disease: testing IBD in vitro
If we take the whole human gastrointestinal (GI) tract and set it straight, it would be about nine meters long: more or less the height of a three-stage building. But don’t picture it like a long, plain tube. It has several compartments with different structures, each one with a specific function: the stomach secretes acids to degrade the food, while … Read More
New Deal News: Team meeting in Vigo
During our stay in Vigo, we had the chance to review the advances of the past six months going over our the most important results from all our partners and troubleshooting critical points. We also had time to discuss our global progress and together define the next steps that will be key for the success of the project. As closure … Read More
Silencing IBD: when a tiny molecule can make a great difference.
Take a quick look on your body. We are a combination of one hundred thousand billion cells. Inside each one of them, we can find all our DNA that holds more than twenty thousand genes. DNA remains in the cell nucleus and, when its information is needed, it doesn’t leave it. Instead, it is transcribed in a different kind of … Read More
INSERM meets IDIBAPS
Sharing knowledge and experiences is key for a successful project! And that’s why our partners from INSERM and IDIBAPS are working together in Barcelona these days. For a few weeks both teams will join forces and work in close collaboration to perform biodistribution and efficacy assays. Keep up the good work!
Success in Barcelona: 4th General Assembly and first review meeting
The months keep passing by and at New Deal we continue striving to develop a new treatment against IBD. Our partner institutions are working in parallel in countries across Europe and thus, regularly putting all this efforts in common face to face is key to keep the project on track. With this idea in mind, we gathered earlier this month … Read More
